Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

102 results about "Impromidine" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Impromidine (INN) is a highly potent and specific histamine H₂ receptor agonist. It has been used diagnostically as a gastric secretion indicator.

3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

InactiveUS20090181963A1Effective amountOrganic active ingredientsOrganic chemistryKinasePI3-Kinase Inhibitors

The invention relates to 3H-[1,2,3]triazolo[4,5-d]pyrimidine compounds of the Formula 1:or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

Owner:WYETH LLC

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

InactiveUS20120277424A1Improve abilitiesPreventing and treating diseaseOrganic active ingredientsBiocideDiseasePTK Inhibitors

Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient.

Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

Owner:KOREA INST OF SCI & TECH

Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents

InactiveCN1439010AOrganic active ingredientsNervous disorderJanus kinase 3Pyrrole

A compound of Formula (I), wherein R1, R2 and R3 are as defined herein, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.

Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents

Owner:PFIZER PRODS ETAT DE CONNECTICUT

Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases

InactiveUS20030229103A1BiocideOrganic chemistryDiseaseDicarboxylic acid

Abstract of Disclosure Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula I. These compounds are found to possess the property of selectively inhibiting collagenase (MMP). They may therefore be useful in prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13.

Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases

Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases

Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases

Owner:SANOFI AVENTIS DEUT GMBH

Fused pyrimidines and substituted quinazolines as inhibitors of p97

ActiveUS20140024661A1BiocideNervous disorderQuinazolineDisease injury

A group of fused two ring pyrimidine compounds having a heterocycles substituent at the 2 position and a substituted amine at the 4 position as well as optional aliphatic, functional and / or aromatic components substituted at other positions of the pyrimidine and other ring are disclosed. In addition a group of quinazoline compounds having similar substituents at the 2 and 4 positions as well as at other positions are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity.

Fused pyrimidines and substituted quinazolines as inhibitors of p97

Fused pyrimidines and substituted quinazolines as inhibitors of p97

Fused pyrimidines and substituted quinazolines as inhibitors of p97

Owner:EIKON THERAPEUTICS INC

4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them

InactiveCN101421250AOrganic chemistryArylImpromidine

This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R<1>, R<2>, R<25>, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them

4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them

4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them

Owner:EXELIXIS INC

Protein tyrosine kinase modulators and methods of use

InactiveCN105377835AOrganic active ingredientsOrganic chemistryKinase activityTyrosine Protein Kinases

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and / or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative,and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

Protein tyrosine kinase modulators and methods of use

Protein tyrosine kinase modulators and methods of use

Protein tyrosine kinase modulators and methods of use

Owner:BETTA PHARM CO LTD

Phosphoinositide 3-kinase (P13K) inhibitor, pharmaceutical composition containing P13K inhibitor, and application of phosphoinositide kinase inhibitor and pharmaceutical composition

ActiveCN103483345AImprove effectivenessGood choiceOrganic active ingredientsOrganic chemistryKinase inhibitionEnzyme inhibitor

The invention discloses a phosphoinositide 3-kinase (P13K) inhibitor, a pharmaceutical composition containing the P13K inhibitor, and application of the P13K inhibitor and the pharmaceutical composition. The P13K inhibitor comprises a pyrimidine compound and a stereoisomer / hydrate / pharmaceutically-acceptable salt thereof. The pyrimidine compound has a general formula I of which the structure is shown in the specification. The P13K inhibitor and the pharmaceutical composition containing the same can be used for inhibiting PI3 Ks and treating proliferative diseases on which the PI3 Ks act. According to the invention, high-effectiveness and high-selectivity inhibitors for treating proliferative diseases on which PI3Ks act can be provided.

Phosphoinositide 3-kinase (P13K) inhibitor, pharmaceutical composition containing P13K inhibitor, and application of phosphoinositide kinase inhibitor and pharmaceutical composition

Phosphoinositide 3-kinase (P13K) inhibitor, pharmaceutical composition containing P13K inhibitor, and application of phosphoinositide kinase inhibitor and pharmaceutical composition

Phosphoinositide 3-kinase (P13K) inhibitor, pharmaceutical composition containing P13K inhibitor, and application of phosphoinositide kinase inhibitor and pharmaceutical composition

Owner:SUN YAT SEN UNIV

Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds

InactiveUS6962914B2BiocideOrganic chemistryPyridinePyrazolopyridine

The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds

Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds

Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds

Owner:SMITHKLINE BECKMAN CORP

Protein tyrosine kinase modulators and methods of use

InactiveUS20160145237A1Conveniently preparedPoor growthBiocideSenses disorderKinase activityDisease

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and / or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

Protein tyrosine kinase modulators and methods of use

Protein tyrosine kinase modulators and methods of use

Protein tyrosine kinase modulators and methods of use

Owner:BETTA PHARM CO LTD

Pyrimidine compounds as serotonin receptor modulators

ActiveUS7598255B2BiocideSilicon organic compounds5-HT receptorReceptor modulator

Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases.

Pyrimidine compounds as serotonin receptor modulators

Pyrimidine compounds as serotonin receptor modulators

Pyrimidine compounds as serotonin receptor modulators

Owner:JANSSEN PHARMA NV

Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications

InactiveUS20080279785A1Allow flexibilityModulate immune responseOrganic active ingredientsPeptide/protein ingredientsPurineCG-dinucleotide

The invention relates to the therapeutic use of oligonucleotides as immune modulatory agents in immunotherapy applications. More particularly, the invention provides immune modulatory oligonucleotide compositions for use in methods for generating an immune response or for treating a patient in need of immune modulation. The immune modulatory oligonucleotides of the invention preferably comprise novel pyrimidines and purines.

Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications

Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications

Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications

Owner:IDERA PHARMA INC

2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer

InactiveUS8530650B2BiocideSenses disorderAutotaxinAcid level

The present invention relates to pyridopyrimidine derivatives according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and / or prophylaxis of physiological and / or pathophysiological conditions, which are caused, mediated and / or propagated by increased lysophosphatic acid levels and / or the activation of autotaxin, in particular of different cancers.

2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer

2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer

2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer

Owner:MERCK PATENT GMBH

Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors

InactiveUS7648986B2High viscosityBiocideSenses disorderCoronary heart diseaseTyrosine-kinase inhibitor

Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors

Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors

Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors

Owner:BAYER SCHERING PHARMA AG

2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (BACE)

ActiveUS7531545B2BiocideOrganic active ingredientsDiseaseMedicinal chemistry

The present invention is directed to novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (BACE)

2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (BACE)

2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (BACE)

Owner:JANSSEN PHARMA NV

4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use

InactiveUS7429574B2Improve throughputLimit deliveryBiocideSenses disorderDiseasePurine

Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.

4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use

4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use

4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use

Owner:OSI PHARMA INC

Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists

InactiveUS20100113479A1Inadequate glucose toleranceBiocideOrganic active ingredientsDiabetes mellitusD-Glucose

The present invention is directed to novel processes for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists

Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists

Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists

Owner:ARENA PHARMA

Substituted quinazoline and pyrido-pyrimidine derivatives

InactiveUS8440662B2Organic active ingredientsOrganic chemistryDiseasePyridine

The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and / or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K / AKT / mTOR pathway. Advantageously, these compounds perform as dual PI3K / mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Substituted quinazoline and pyrido-pyrimidine derivatives

Substituted quinazoline and pyrido-pyrimidine derivatives

Substituted quinazoline and pyrido-pyrimidine derivatives

Owner:ASANA BIOSCI

Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists

ActiveUS20080194576A1Organic active ingredientsOrganic chemistryDiseaseMammal

The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and / or prevention and / or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists

Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists

Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists

Owner:IDORSIA PHARM LTD

Ligands for aggregated tau molecules

ActiveUS20110171739A1Organic chemistryDisease diagnosisImidazothiazolePyridine

Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

Ligands for aggregated tau molecules

Ligands for aggregated tau molecules

Ligands for aggregated tau molecules

Owner:WISTA LAB LTD

Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

InactiveCN102459272AOrganic active ingredientsNervous disorderImmunologic disordersDisease

Formula (I) ((Ia) and (Ib)) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Owner:GENENTECH INC +1

4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines

ActiveUS20100069396A1Nervous disorderOrganic chemistryDiseaseCCR1

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines

4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines

4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines

Owner:CHEMOCENTRYX INC

Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

InactiveCN1867553AOrganic active ingredientsSenses disorderDiseaseVEGF receptors

The present invention relates to pyrimidine derivatives of formula (I), which are useful as inhibitors of cyclin-dependent kinases and VEGF receptor tyrosine kinases. The present invention also relates to a method for preparing the derivative and its use as a medicine for treating various diseases.

Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

Owner:BAYER IP GMBH

Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines

ActiveCN103087077ANovel structureStrong inhibitory activityOrganic active ingredientsOrganic chemistryDiseaseTyrosine-kinase inhibitor

The invention discloses a thienopyrimidine and furopyrimidine derivative, its preparation method and its application in medicines. The derivative is a compound shown as general formula I, general formula II, general formula III or general formula IV. The thienopyrimidine and furopyrimidine pyrimidine derivative provided in the invention has an obvious EGFR (epidermal growth factor receptor) inhibitory activity, and some of the compounds also have an obvious inhibitory activity on VEGFR (vascular endothelial growth factor receptor), so that the thienopyrimidine and furopyrimidine pyrimidine derivative can be expected to be developed into tyrosine kinase EGFR or / and VEGFR inhibitors, which can be used for preparation of drugs preventing or treating diseases related to EGFR and / or VEGFR. Therefore, the derivative provided in the invention provides a new development direction and approach for developing novel tyrosine kinase inhibitor drugs that have low resistance or can alleviate early inhibitor resistance, and has wide application prospect and medicinal value.

Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines

Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines

Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines

Owner:JIANGSU DESANO PHARMA

Pyrazolo 1,5-a pyrimidine derivatives

InactiveCN100482665CGood kinase inhibitory activityOrganic active ingredientsSenses disorderImmunologic disordersDisease

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and / or tumour growth.

Pyrazolo 1,5-a pyrimidine derivatives

Pyrazolo 1,5-a pyrimidine derivatives

Pyrazolo 1,5-a pyrimidine derivatives

Owner:TEIJIN PHARMA CO LTD

Quinazoline, pyridopyrimidine or pyrimidopyrimidine derivative epidermal growth factor inhibitor and preparing method and application thereof

InactiveCN106496196AStrong inhibitory activityReduced inhibitory activityOrganic active ingredientsOrganic chemistryDiseaseProtein-Tyrosine Kinases

The invention discloses a selectivity inhibitor of a clinical mutant of EGFR protein tyrosine kinase. The selectivity inhibitor of the clinical mutant of EGFR protein tyrosine kinase has a structure which is shown in the formula (1) (The formula (1) is defined in the description), and is a double aromatic nucleus template compound containing quinazoline, pyridopyrimidine or pyrimidopyrimidine. The invention further discloses a preparing method of the compound and an application of the compound as the selectivity inhibitor of the clinical mutant of EGFR protein tyrosine kinase, especially an inhibiting effect of the compound in a T790M-variation EGFR and an application in treating diseases such as renal carcinoma, lung cancer, prostate gland cancer, pancreatic cancer, breast cancer and spongiocytoma, wherein the diseases are related to overexpression of the epidermal growth factor receptor EGFR.

Quinazoline, pyridopyrimidine or pyrimidopyrimidine derivative epidermal growth factor inhibitor and preparing method and application thereof

Quinazoline, pyridopyrimidine or pyrimidopyrimidine derivative epidermal growth factor inhibitor and preparing method and application thereof

Quinazoline, pyridopyrimidine or pyrimidopyrimidine derivative epidermal growth factor inhibitor and preparing method and application thereof

Owner:NANJING LEIKEXING BIOTECH CO LTD

Pyrimidine derivatives and their use as P2Y12 receptor antagonists

ActiveUS8048881B2Organic active ingredientsOrganic chemistryDiseaseNK1 receptor antagonist

The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and / or prevention and / or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Pyrimidine derivatives and their use as P2Y12 receptor antagonists

Pyrimidine derivatives and their use as P2Y12 receptor antagonists

Pyrimidine derivatives and their use as P2Y12 receptor antagonists

Owner:IDORSIA PHARM LTD

4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines

ActiveUS8343975B2Nervous disorderOrganic chemistryDiseaseCompetitive antagonist

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines

4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines

4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines

Owner:CHEMOCENTRYX INC

Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

ActiveUS20150210702A1BiocideOrganic active ingredientsDiseaseMedicine

The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX / ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and / or the respective pathways.

Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Owner:ACEA THERAPEUTICS INC

Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity

InactiveUS20170119766A1Organic chemistryBoron compound active ingredientsBruton's tyrosine kinasePyridine

The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).

Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity

Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity

Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity

Owner:MERCK PATENT GMBH

Popular searches

Pyrimidine Abnormal cell Israpafant Protein kinase C Chemistry Kinase protein Thiophene Signal transduction Protein kinase inhibitor Growth factor

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com